Eliquis — Total Revenues
Bristol-Myers Squibb Eliquis — Total Revenues increased by 1.8% to $3.75B in Q3 2025 compared to the prior quarter. Year-over-year, this metric grew by 24.8%, from $3.00B to $3.75B. Over 3 years (FY 2021 to FY 2024), Eliquis — Total Revenues shows an upward trend with a 7.4% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
How to read this metric
An increase indicates strong market adoption and sustained demand for the product, while a decrease may signal rising competition, patent expirations, or shifts in healthcare reimbursement policies.
Detailed definition
This metric represents the total global net sales generated by the anticoagulant medication Eliquis. As a cornerstone pr...
Peer comparison
Comparable to revenue metrics for blockbuster pharmaceutical products at peer companies, often evaluated against patent cliffs and market penetration rates.
bmy_segment_eliquis_total_revenuesHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $2.79B | $2.41B | $2.67B | $3.21B | $3.24B | $2.66B | $2.69B | $3.42B | $3.20B | $2.71B | $2.87B | $3.72B | $3.42B | $3.00B | $3.20B | $3.57B | $3.68B | $3.75B |
| QoQ Change | — | -13.6% | +10.7% | +20.2% | +0.7% | -17.9% | +1.2% | +27.3% | -6.4% | -15.6% | +6.2% | +29.4% | -8.2% | -12.1% | +6.4% | +11.6% | +3.2% | +1.8% |
| YoY Change | — | — | — | — | +15.9% | +10.0% | +0.6% | +6.6% | -1.0% | +1.9% | +6.9% | +8.7% | +6.6% | +11.0% | +11.2% | -4.2% | +7.7% | +24.8% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Bristol-Myers Squibb's eliquis — total revenues?
- Bristol-Myers Squibb (BMY) reported eliquis — total revenues of $3.75B in Q3 2025.
- How has Bristol-Myers Squibb's eliquis — total revenues changed year-over-year?
- Bristol-Myers Squibb's eliquis — total revenues increased by 24.8% year-over-year, from $3.00B to $3.75B.
- What is the long-term trend for Bristol-Myers Squibb's eliquis — total revenues?
- Over 3 years (2021 to 2024), Bristol-Myers Squibb's eliquis — total revenues has grown at a 7.4% compound annual growth rate (CAGR), from $10.76B to $13.33B.
- What does eliquis — total revenues mean?
- The total revenue generated from the sales of the anticoagulant drug Eliquis.